Home / About Us
Home / Innovation/ PANDA Trial

What is KH631？

The first-generation gene therapy product KH631 is for unmet medical needs of ocular diseases by utilizing the naturally occurring adeno-associated vector (AAV) library platform, which has huge market potential.

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Brief Summary:

VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections.

Condition or disease：

Neovascular Age-related Macular Degeneration

Arms and Interventions：

Arms Intervention/treatment 
Experimental: KH631 Dose 1
KH631 One-Time Intraocular Injection Dose Level 1 		Drug: KH631
KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Experimental: KH631 Dose 2
KH631 One-Time Intraocular Injection Dose Level 2 		Drug: KH631
KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Experimental: KH631 Dose 3
KH631 One-Time Intraocular Injection Dose Level 3 		Drug: KH631
KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Experimental: KH631 Dose 4
KH631 One-Time Intraocular Injection Dose Level 4 		Drug: KH631
KH631: AAV vector containing a coding sequence for an anti-VEGF protein

The clinical trial data for KH631